{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:15:33Z","timestamp":1761743733758},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ejca.2013.03.022","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T17:55:55Z","timestamp":1366221355000},"page":"2504-2511","source":"Crossref","is-referenced-by-count":8,"title":["The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors \u2013 Is there more to come?"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct01223027","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel Stuart","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ejca.2013.03.022_b0005","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.022_b0010","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.022_b0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2013.03.022_b0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2011.06.017","article-title":"ICUD-EAU international consultation on kidney cancer 2010: treatment of metastatic disease","volume":"60","author":"Patard","year":"2011","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejca.2013.03.022_b0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"N\u00e9grier","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl. 9","key":"10.1016\/j.ejca.2013.03.022_b0030","article-title":"Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); results of the COMPARZ trial","volume":"23","author":"Motzer","year":"2012","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2013.03.022_b0035","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.022_b0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.eururo.2008.07.051","article-title":"Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis","volume":"54","author":"Eichelberg","year":"2008","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.022_b0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.eururo.2011.07.037","article-title":"Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors","volume":"60","author":"Busch","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.022_b0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2011.10.032","article-title":"Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?","volume":"61","author":"Sonpavde","year":"2012","journal-title":"Eur Urol"},{"issue":"Suppl. 9","key":"10.1016\/j.ejca.2013.03.022_b0055","article-title":"Temsirolimus vs sorafenib as second-line therapy in metastatic renal cell carcinoma: phase 3 results from the INTORSECT trial","volume":"23","author":"Hutson","year":"2012","journal-title":"Ann Oncol"},{"issue":"9807","key":"10.1016\/j.ejca.2013.03.022_b0060","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"15_suppl.","key":"10.1016\/j.ejca.2013.03.022_b0065","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/jco.2012.30.15_suppl.4501","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2013.03.022_b0070","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.022_b0075","first-page":"A3780","article-title":"Further characterization of the potent VEGF\/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activity","volume":"44","author":"Wickman","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.022_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2013.03.022_b0085","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.ejca.2013.03.022_b0090","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2013.03.022_b0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.mri.2006.09.041","article-title":"AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging","volume":"25","author":"Wilmes","year":"2007","journal-title":"Magn Reson Imaging"},{"issue":"24","key":"10.1016\/j.ejca.2013.03.022_b0100","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2013.03.022_b0105","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1200\/JCO.2005.04.143","article-title":"Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"23","author":"Liu","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2013.03.022_b0110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-011-1171-8","article-title":"Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics","volume":"68","author":"Brennan","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.022_b0115","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s10637-010-9477-4","article-title":"Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics","volume":"29","author":"Tortorici","year":"2011","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.022_b0120","first-page":"594","article-title":"In vitro selectivity and potency of KRN951, a novel inhibitor of VEGF receptor tyrosine kinases","volume":"2004","author":"Nakamura","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.022_b0125","first-page":"1375","article-title":"The VEGF receptor inhibitor KRN951 decreases vascular permeability in tumors and inhibits tumor growth: an analysis using dynamic contrast-enhanced magnetic resonance imaging","volume":"2005","author":"Nakamura","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.022_b0130","first-page":"1373","article-title":"The efficacy of KRN951, a novel VEGF receptor tyrosine kinase inhibitor, in intraperitoneal disseminated tumor models","volume":"2005","author":"Taguchi","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2013.03.022_b0135","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1158\/1078-0432.CCR-11-0411","article-title":"Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors","volume":"17","author":"Eskens","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11 Meeting Abstracts","key":"10.1016\/j.ejca.2013.03.022_b0140","article-title":"A phase 1 study to evaluate the absorption, metabolism, and excretion of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) tivozanib","volume":"10","author":"Cotreau","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"10.1016\/j.ejca.2013.03.022_b0145","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2011.35.3524","article-title":"Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma","volume":"30","author":"Nosov","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15_suppl.","key":"10.1016\/j.ejca.2013.03.022_b0150","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1200\/jco.2011.29.15_suppl.4549","article-title":"Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC)","volume":"29","author":"Kabbinavar","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4_suppl.","key":"10.1016\/j.ejca.2013.03.022_b0155","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/jco.2012.30.4_suppl.560","article-title":"Multicenter phase Ib\/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer","volume":"30","author":"Wolpin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2013.03.022_b0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2013.03.022_b0165","article-title":"Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trial","volume":"29","author":"Motzer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2013.03.022_b0170","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"year":"2011","series-title":"FDA briefing document. Oncological drugs advisory committee meeting","author":"Axitinib (Inlyta\u00ae), Pfizer, Inc","key":"10.1016\/j.ejca.2013.03.022_b0175"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2013.03.022_b0180","article-title":"Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial)","volume":"47","author":"Escudier","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.03.022_b0185","doi-asserted-by":"crossref","first-page":"793PD","DOI":"10.1016\/S0923-7534(20)33351-2","article-title":"Axitinib vs sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors","volume":"23","author":"Motzer","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.03.022_b0190","first-page":"129","article-title":"Molecular targeted therapies for solid tumors: management of side effects","volume":"32","author":"Gr\u00fcnwald","year":"2009","journal-title":"Onkologie"},{"issue":"26","key":"10.1016\/j.ejca.2013.03.022_b0195","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2013.03.022_b0200","article-title":"Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects","volume":"42","author":"Joly","year":"2006","journal-title":"Eur J Cancer Suppl"},{"issue":"Suppl. 12","key":"10.1016\/j.ejca.2013.03.022_b0205","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1158\/1535-7163.TARG-09-A13","article-title":"Abstract A13: reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184 \u2013 Sennino et al. 8 (1001): A13 \u2013 molecular cancer therapeutics","volume":"8","author":"Sennino","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.ejca.2013.03.022_b0210","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2013.03.022_b0215","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","article-title":"HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors","volume":"70","author":"Shojaei","year":"2010","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.ejca.2013.03.022_b0220","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.022_b0225","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(09)70380-8","article-title":"Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new","volume":"11","author":"Furge","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2013.03.022_b0230","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl.","key":"10.1016\/j.ejca.2013.03.022_b0235","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1200\/jco.2011.29.15_suppl.4516","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial","volume":"29","author":"Hussain","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5_suppl.","key":"10.1016\/j.ejca.2013.03.022_b0240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/jco.2012.30.5_suppl.364","article-title":"Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)","volume":"30","author":"Choueiri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"137","key":"10.1016\/j.ejca.2013.03.022_b0245","doi-asserted-by":"crossref","first-page":"13775","DOI":"10.1126\/scitranslmed.3003643","article-title":"A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma","volume":"4","author":"Sivanand","year":"2012","journal-title":"Sci Transl Med"},{"issue":"15_suppl.","key":"10.1016\/j.ejca.2013.03.022_b0250","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1200\/jco.2011.29.15_suppl.4551","article-title":"A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)","volume":"29","author":"Angevin","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2013.03.022_b0255","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/1078-0432.CCR-07-1466","article-title":"A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"14","author":"Sarker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.03.022_b0260","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/jco.2012.30.15_suppl.2603","article-title":"Dovitinib (TKI258): exploration of pharmacokinetics and pharmacodynamics (PK\/PD) for dose and regimen consideration","volume":"30","author":"Garonzik","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.022_b0265","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/jco.2012.30.5_suppl.354","article-title":"Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study","volume":"30","author":"Rini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2013.03.022_b0270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/jco.2013.31.6_suppl.lba348","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Hutson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.022_b0275","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913002268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913002268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T15:01:20Z","timestamp":1595689280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913002268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0959804913002268"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.03.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}